Sufferers utilizing Novo Nordisk’s NVO NONOF weight problems remedy, Wegovy, have reportedly maintained a mean weight lack of 10% over a four-year interval, as per knowledge revealed by the corporate on Tuesday. This info was shared on the European Congress on Weight problems in Venice, Italy.
What Occurred: The information, derived from a large-scale examine, most of which was revealed final yr, may probably bolster Novo’s case for Wegovy because it makes an attempt to persuade insurers and governments to cowl the price of the drug, countering the notion of it being merely a life-style drug, Reuters reported.
“That is the longest examine we’ve carried out to date of semaglutide for weight reduction,” acknowledged Martin Holst Lange, Novo’s head of improvement.
See Additionally: Benzinga’s ‘Inventory Whisper’ Index: 5 Shares Buyers Secretly Monitor However Don’t Discuss About But
The trial concerned 17,604 sufferers and examined Wegovy not for weight reduction, however for its coronary heart protecting advantages for chubby and overweight sufferers with preexisting coronary heart illness however not diabetes. Members weren’t required to trace weight-reduction plan and train because it was not an weight problems examine.
Why It Issues: Regardless of provide constraints and competitors from Eli Lilly, the demand for Wegovy has been on the rise. The drug’s gross sales greater than doubled to 9.38 billion kroner ($1.35 billion) within the first quarter, though this determine fell in need of analysts’ estimates as a result of pricing stress.
Tesla CEO Elon Musk lately endorsed Novo Nordisk’s Ozempic, a GLP-1 agonist primarily prescribed to handle Sort 2 diabetes, and sparked a dialog about childhood weight problems and potential options.
Then again, Denmark’s healthcare authority has determined to favor cheaper medication for sort 2 diabetes sufferers, impacting the prescription of costlier GLP-1 medication comparable to Novo Nordisk’s Ozempic. This resolution is predicted to have an effect on practically half of all present GLP-1 drug customers, who might swap to cheaper options.
Worth Motion: On Monday, Novo Nordisk closed 3.09% larger on NYSE at $132.39, in keeping with Benzinga Professional.
Learn Subsequent: ‘Barbarism:’ AOC Unleashes Fury On US Healthcare System As Folks Are ‘Selecting Between Medication And Hire’
Picture By way of Shutterstock
Engineered by Benzinga Neuro, Edited by
Pooja Rajkumari
The GPT-4-based Benzinga Neuro content material era system exploits the intensive Benzinga Ecosystem, together with native knowledge, APIs, and extra to create complete and well timed tales for you.
Study extra.
